Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Capetti, Amedeo F
84  Ergebnisse:
Personensuche X
?
1

Unexpected CD4 decay, hidden adherence gaps, resilience, an..:

Mariani, Chiara ; Borgonovo, Fabio ; Gerbi, Martina..
AIDS Care.  , 2024
Link: https://doi.org/10.1080/..
 
?
2

The future of long-acting cabotegravir plus rilpivirine the..:

Rusconi, Stefano ; Santoro, Maria M. ; Capetti, Amedeo F...
International Journal of Antimicrobial Agents.  60 (2022)  3 - p. 106627 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Decay rate of antiS1/S2 IgG serum levels after 6 months of ..:

Borgonovo, Fabio ; Stangalini, Carlo Alberto ; Tinelli, Carmine...
Human Vaccines & Immunotherapeutics.  18 (2022)  5 - p. , 2022
Link: https://doi.org/10.1080/..
 
?
4

Persistence of Long-COVID symptoms in a heterogenous prospe..:

Mariani, Chiara ; Borgonovo, Fabio ; Capetti, Amedeo F...
Journal of Infection.  84 (2022)  5 - p. 722-746 , 2022
Link: https://doi.org/10.1016/..
 
?
5

Impressive Boosting of Anti-S1/S2 Immunoglobulin G Producti..:

Capetti, Amedeo F ; Stangalini, Carlo A ; Borgonovo, Fabio...
Clinical Infectious Diseases.  73 (2021)  6 - p. e1402-e1403 , 2021
Link: https://doi.org/10.1093/..
 
?
6

One-year durability of anti-spike IgG to SARS-CoV-2: Prelim..:

Capetti, Amedeo F. ; Borgonovo, Fabio ; Mileto, Davide...
Journal of Infection.  83 (2021)  2 - p. 237-279 , 2021
Link: https://doi.org/10.1016/..
 
?
7

Is COVID-19 severity associated with anti-spike antibody du..:

Borgonovo, Fabio ; Passerini, Matteo ; Piscaglia, Marco...
Journal of Infection.  82 (2021)  5 - p. e28-e30 , 2021
Link: https://doi.org/10.1016/..
 
?
8

Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in..:

Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina...
Journal of Medical Virology.  93 (2020)  3 - p. 1766-1769 , 2020
Link: https://doi.org/10.1002/..
 
?
9

Is Dolutegravir Plus Atazanavir Overburdened With Concentra..:

Capetti, Amedeo F ; Atzori, Chiara ; Cossu, Maria V...
Open Forum Infectious Diseases.  6 (2019)  2 - p. , 2019
Link: https://doi.org/10.1093/..
 
?
10

A dual regimen of ritonavir/darunavir plus dolutegravir for..:

Capetti, Amedeo F. ; Cossu, Maria Vittoria ; Orofino, Giancarlo...
BMC Infectious Diseases.  17 (2017)  1 - p. , 2017
Link: https://doi.org/10.1186/..
 
?
11

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cAR..:

Capetti, Amedeo F. ; Sterrantino, Gaetana ; Cossu, Maria Vittoria...
PLOS ONE.  11 (2016)  10 - p. e0164753 , 2016
Link: https://doi.org/10.1371/..
 
?
12

The future of long-acting cabotegravir plus rilpivirine the..:

Rusconi, Stefano ; Santoro, Maria ; Capetti, Amedeo F..
info:eu-repo/semantics/altIdentifier/pmid/35760225.  , 2022
Link: http://hdl.handle.net/21..
 
?
13

Decay rate of antiS1/S2 IgG serum levels after 6 months of ..:

Borgonovo, Fabio ; Stangalini, Carlo Alberto ; Tinelli, Carmine...
info:eu-repo/semantics/altIdentifier/pmid/35511791.  , 2022
Link: https://hdl.handle.net/2..
 
?
14

Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in..:

Capetti, Amedeo F ; Borgonovo, Fabio ; Morena, Valentina...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891345/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
15

Is Dolutegravir Plus Atazanavir Overburdened With Concentra..:

Capetti, Amedeo F ; Atzori, Chiara ; Cossu, Maria V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386800/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
1-15